Your new experience awaits. Try the new design now and help us make it even better

MINI REVIEW article

Front. Cardiovasc. Med.

Sec. Cardiovascular Biologics and Regenerative Medicine

Volume 12 - 2025 | doi: 10.3389/fcvm.2025.1642931

This article is part of the Research TopicGenetic and Acquired Disease Modeling with hiPSC-derived CardiomyocytesView all articles

Cardiac Disease Mechanobiology: Advances using hiPSC-CMs

Provisionally accepted
  • University of Michigan, Ann Arbor, United States

The final, formatted version of the article will be published soon.

Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide. Despite advances in diagnosis and treatment, there is a critical need for sophisticated models that accurately reflect human cardiovascular pathophysiology. This mini review explores recent advancements in cardiac microenvironment engineering for modeling cardiac mechanobiology and investigating genetic and acquired cardiac diseases. Cardiac function relies heavily on mechanical cues, with integrin-and cadherin-based adhesion complexes mediating mechanosensitive signaling that drives disease progression. However, studying these processes in humans remains challenging. Although animal models have been indispensable, they often fail to recapitulate human-specific cardiac features. Human-induced pluripotent stem cells (hiPSCs) have been transformative, enabling patient-specific modeling and the identification of diseasespecific phenotypes that are challenging to replicate in traditional animal models. Despite their promise, hiPSC-CMs are constrained by their immature phenotype and heterogeneity, which limits their efficacy in modeling adult cardiac physiology. Emerging in vitro systems, particularly those engineered using biomaterials such as hydrogels, address these limitations by mimicking the mechanical and biochemical environment of native cardiac tissue. We discuss the potential and challenges of these hiPSC-derived cardiomyocytes (hiPSC-CMs) in modeling cardiac mechanotransduction, focusing on the interplay between mechanical stress and cellular maturation, mechanics, and signaling. By integrating advanced biomaterials and genome editing technologies, these in vitro platforms hold the potential to revolutionize cardiac research, offering the prospect of more precise interventions and improved patient outcomes.

Keywords: hiPSC-CMs, mechanobiology, disease modeling, Engineered platforms, Cardiomyopathies

Received: 07 Jun 2025; Accepted: 03 Sep 2025.

Copyright: © 2025 Stephanie and Vander Roest. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Alison Schroer Vander Roest, University of Michigan, Ann Arbor, United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.